Summary High-dose chemotherapy with autologous bone marrow transplantation is used in the treatment of relapsed or high-risk Hodgkin's disease. As From the observation that patients with relapsed disease when treated with conventional chemotherapy have a progression-free survival (PFS) of around 30% and a median survival of 12 months, it has become accepted that fit patients with HD who have a first remission of < 12 months' duration, those who fail to achieve a complete remission (CR) with satisfactory induction therapy including an anthracycline, or those patients who are in second or subsequent relapse, or high-risk patients in first relapse, should be treated in this way Longo et al., 1992 . The trial demonstrates the difficulty in recruiting to a trial in which one of the treatment modalities, although unproven, is seen to be the best chance of long-term survival. A few years into this randomised study, patients were refusing to be randomised and requested high-dose treatment.
index
The mortality rate of patients receiving high-dose chemotherapy with haematological support in the form of autologous bone marrow transplantation (ABMT) has improved with better patient selection, supportive medicine and the use of peripheral blood stem cells and growth factors (Peters, 1993) . This procedure remains unproven in Hodgkin's disease (HD) and at present decisions are based on the results reported in one randomised trial and other retrospective series of patients treated at different stages of HD when drug resistance is either present or beginning to appear.
From the observation that patients with relapsed disease when treated with conventional chemotherapy have a progression-free survival (PFS) of around 30% and a median survival of 12 months, it has become accepted that fit patients with HD who have a first remission of < 12 months' duration, those who fail to achieve a complete remission (CR) with satisfactory induction therapy including an anthracycline, or those patients who are in second or subsequent relapse, or high-risk patients in first relapse, should be treated in this way Longo et al., 1992) .
Lohri et al. (1991) described a group of 80 patients after first relapse HD treated by four different treatment regimens including one group of 16 patients who received high-dose chemotherapy with ABMT. Freedom from second relapse was the end point and was similar in all groups. More recently the Vancouver group have reported their experience with high-dose treatment in a group of HD patients after first relapse from initial complete remission and compared the outcome with that in patients treated with conventional chemotherapy (Reece et al., 1994 Conditioning regimens Melphalan as a single agent (180-220 mg m-2) was used in the first phase of the study in ten patients. BCNU (300-600 mg m-2) was then added to the melphalan (80-140 mg m-2) and given to 11 patients and then etoposide The three untested relapses were not included in the Cox's analysis and the analysis was repeated with and without the patients in first CR (n = 7) and first PR (n = 1). Neither of these omissions significantly changed any results.
An early treatment-related death was defined as a death within 2 months of ABMT. After the initial 2 month transplant period subsequent events have been termed late toxicities.
Results
Response rate A total of 24 patients were in CR at the time of ABMT, 33 achieved CR with ABMT, 16 PR, 16 NR and three early treatment deaths (two of these patients were in CR before ABMT) to give a response rate to ABMT of 49/65=74% (95% CI 60-83%) with a CR rate of 33/65=51% (CI 36-62%). A total of 57/89=64% of patients were therefore in CR at the end of the procedure.
Primary refractory disease and resistant relapses (Table II) In all, 6/11 patients had a complete remission. Two of these patients developed pneumonitis and died without relapsed disease, both had a BCNU dose of 600 mg m-2, one had mediastinal radiotherapy and both had received two previous chemotherapy regimens. One patient in CR died of infection having had four previous treatment regimens, two patients have relapsed and only one remains in remission 56 months later.
In the group of resistant relapses, no CR were documented and 6/13 patients achieved a PR, 4/6 have died of progressive disease, one is alive at 20 months in continued PR and one The details of the six patients who died of lung toxicity will be the subject of a separate publication. There were two cases of leukaemia in the remission group and as these patients were heavily pretreated this is not considered a direct toxicity of the high-dose therapy. One patient with progressive disease going into high-dose treatment died of a protein-losing enteropathy 2.5 months after treatment and unfortunately no post-mortem was permitted. One patient with a background of a depressive personality, in remission, committed suicide 4.5 years after high-dose treatment. Thus the late toxic mortality rate overall is 8/86=9%, or including the three early toxic deaths 11/ 89 =12% and in the complete remission patients the late toxic mortality rate was 7/55 = 13%.
Second malignancies (Table III) There were three deaths from second malignancies: one acute myeloid leukaemia, one myelodysplastic syndrome with subsequent leukaemia, in two patients in remission at 4 and 6 years, and one high-grade non-Hodgkin's lymphoma at 3 years in a patient with active HD. A fourth patient, aged 38 years, died of active HD but had also developed a squamous carcinoma of the oral mucosa.
Survival
All patients are included in the survival analysis. Survival overall is shown in Figure 1 with a 5 year survival of 41%.
Progression-free survival (PFS) and time to progression The median PFS overall is 17 months with 40% alive and progression-free at 5 years ( Figure 2) . However, for those in CR at the time of ABMT or afterwards the probability of albumin at ABMT in g dl-I (<35, >35). The outcome following the most recent treatment before high-dose treatment (with or without the three untested) was the most significant factor for both progression-free survival (chisquared test=9.69, P<0.025, Figure 3 ) and overall survival (P= 0.02). Treatment/response history in two groups as follows: <3 regimens or previous CR as one group or >3 regimens but never CR as a second group, was also significant for progression-free survival and survival (P=0.004 and P=0.01 respectively). <3 Tx or CR ever (n = 76) (Table IV) A Cox's multivariate analysis produced a model in which response to the chemotherapy regimen before ABMT and treatment/response history were the factors which predicted long-term freedom from progression with this procedure (Table IV, Figures 3 and 4) . No other additional factor improved the fit. Putting these two groups together produced four Cox groups A-D (A, CR to most recent treatment; B, PR to most recent treatment, CR previously or < 3 regimens; C, NR/PD to most recent treatment, CR previously or <3 regimens; D, never CR and >3 regimens) to give a predictive model shown in Figure 5 . This model divides the patient population broadly into a group of 56/86 (65%) patients (Cox group A + B, i.e. CR or PR to most recent treatment and a CR previously or <3 previous treatment regimens) with at least a 70% chance of being progression free from 1 year onwards and the other groups (Cox group C, D) with a poorer prognosis (chi-square = 12.46, P<0.01). If response to the last chemotherapy was excluded from the model, then the category at ABMT (e.g. sensitive relapse etc.) produced a model which was nearly as good as the model constructed using sensitivity to the previous chemotherapy regimen (Table IV, Figure 6 ).
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Discussion
There have been two reports from this centre on the use of high-dose treatment in Hodgkin's disease (Zulian et al., 1989; Harding et al., 1992) . For this analysis the database has been updated and status of disease and response to previous treatment and high-dose treatment verified by two physicians. In addition, some patients in the earlier report were treated with single-agent melphalan at suboptimal doses (<140 mg m-2) and are now excluded. There are now 89 patients with a median follow-up of survivors of 43 months (range 6-77 months), which means that this is one of the larger series in the literature and meaningful interpretation can be given to both the survival and progression-free survival data and to the results of a multivariate analysis on the prediction of response to this treatment.
For patients who achieved a CR before ABMT, the plateau on the graph is at 75% with no late relapses. For PRs before high-dose chemotherapy, the plateau occurs after 45 months and remains at 60%. There is also a plateau on the graph for the group of NR/PD after 15 months and remaining at 33%. At this point in our series we have three cases of second malignancies that have resulted in death. Our acute toxicities were due in most cases to lung disease which can now be predicted and avoided in many cases by reduction of the BCNU dose and the early use of steroids.
To date, the 'category' at ABMT as originally described for non-Hodgkin's lymphoma, e.g. resistant relapses etc., has been the gold standard for response assessment. This categorisation does produce a model very similar to that obtained using response to last chemotherapy but only when response to last chemotherapy has been excluded from the analysis (Figure 6 ). However, retrospective assessment of response is difficult, with the possible exception of a CR. Our prognostic model has been constructed using the hard end points of previous treatment, namely the attainment of a CR ever, the number of previous chemotherapy regimens and the response to the chemotherapy before high-dose therapy. Using this approach we have been able reliably to select the group of patients for whom high-dose chemotherapy will be most successful (hazard ratio= 1) and identify poor risk cases. This prognostic index remains unproven but could easily be applied to bone marrow transplantation registry data. Table V summarises the larger reported series of similar patients treated with high-dose chemotherapy with a median follow-up of at least 24 months and at least 25 patients in each series. This is an attempt to compare our results with other groups. Jones et al. (1990) reported their series of 50 patients which included 21 patients treated with an allograft and found that a complete or partial remission at the time of transplant was not a significant prognastic factor, but the presence of sensitive disease at the time of transplantation was a favourable prognostic sign for surviving event-free. The efficacy of high-dose chemotherapy with bone marrow rescue has been shown to be greater when there is some degree of sensitivity to the therapy (Lohri et al., 1991; Carella et al., 1988; Jagannath et al., 1989) Lohri et al. (1991) also reported a very strong negative impact on outcome in patients with stage IV disease at presentation, recurrence within a year of primary treatment or presence of B symptoms ar recurrence. We did not find any of these factors to be significant in our study as most have been employed to predict response to second line therapy whereas most of our patients were at different stages in their disease, usually much later when the duration of first response may not have been relevant. In addition, like so many other high-dose experiences, the group is made up of a number of subtypes of disease and the paucity of numbers in each group makes any interpretation meaningless; a meta-analysis may help in the subgroup analysis.
This prognostic index should now be applied to a large series of patients with Hodgkin's disease who have received high-dose treatment.
